Is Pfizer Inc.’s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials?
With its stock down 7.6% over the past three months, it is easy to disregard Pfizer (NYSE:PFE). We, however decided to study the company’s financials to determine if they have got anything to do with the price decline. Fundamentals usually dictate market outcomes so it makes sense to study the company’s financials. In this article, we decided to focus on Pfizer’s ROE.
Return on equity or ROE is a key measure used to assess how efficiently a company’s management is utilizing the company’s capital. Put another way, it reveals the company’s success at turning shareholder investments into profits.
ROE can be…
